Recently, Syamprasad et al. indicated that the aldose reductase inhibitor epalrestat and its analog NAR1-29 could be combined with antidiabetic therapy to combat diabetes-induced MASLD and even HCC [65]. Here, AKR1B1 is linked to hepatocellular carcinoma.